pentadecapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
=== International activities === Since 2021 when its restaurants in China closed, White Castle does not currently have any restaurants outside of the continental United States. Through franchise deals with local corporate business partners, White Castle briefly had restaurants outside of the United States in Singapore, Malaysia, and Japan during the late 1980s and early 1990s, but the concept never caught on in those countries. During the same time period, White Castle also tried to establish franchised operations in Mexico and South Korea, but these restaurants also failed. The lone Korean restaurant in Seoul was quietly closed by 1993. In 1986, White Castle opened its first Japanese restaurant in the city of Osaka via a franchise deal with a Japanese company. There are no reliable records that show when this location closed. By the end of 1986, the Japanese franchise had six restaurants with a seventh opened by the following year. In June 1989, White Castle and its local franchise partner Innovest Bhd. opened seven restaurants in Malaysia. Innovest franchise territory included Malaysia and Singapore, and the company had plans to open three more restaurants by the end of the year, with the possibility of having a total of 20 restaurants within its two country region by the following year. The first White Castle franchised location in Mexico opened in Mexico City in 1996, but it also closed after a brief trial run. In 2017, White Castle opened its first and second restaurants in China in the city of Shanghai through a partnership with Shanghai-based ClearVue Partners.
=== Immunoliposome therapy === Immunoliposomes are antibody-conjugated liposomes. Liposomes can carry drugs or therapeutic nucleotides and when conjugated with monoclonal antibodies, may be directed against malignant cells. Immunoliposomes have been successfully used in vivo to convey tumour-suppressing genes into tumours, using an antibody fragment against the human transferrin receptor. Tissue-specific gene delivery using immunoliposomes has been achieved in brain and breast cancer tissue.
== Mechanism of action == An average dairy cow begins her lactation with a moderate daily level of milk production. This daily output increases until, at about 70 days into the lactation, production peaks. From that time until the cow is dry, production slowly decreases. This increase and decrease in production is partially caused by the count of milk-producing cells in the udder. Cell counts begin at a moderate number, increase during the first part of the lactation, then decrease as the lactation proceeds. Once lost, these cells generally do not regrow until the next lactation. Administration of rBST or BST prior to peak production, in cows that are well-fed, slows the rate at which the number of mammary cells decreases, and increases the amount of nutrients directed away from fat and toward the mammary cells, leading to an extension of peak milk production. The effects are mediated by the insulin-like growth factor (IGF) system, which is upregulated in response to BST or rBST administration in well-fed cows.
The Imperial Gazetteer of India. Assistance by A. W. Alcock. Oxford: The Claredon Press. Raugh, Harold E. (2004). The Victorians at war, 1815–1914: an encyclopaedia of British military history. s. Robson, Brian (2007). The Road to Kabul. Stroud, Gloucestershire: Spellmount. ISBN 978-1-86227-416-7. Roger, Alexander (2003). Battle Honours of the British Empire and Commonwealth Land Forces 1662–1991. Marlborough: Crowood Press. ISBN 1-86126-637-5. Spilsbury, Julian (2007). The Indian Mutiny. Jouve, France: Orion Publishing Group. p. 9. ISBN 9780297856306. Sumner, Ian (2001). The Indian Army 1914-1947. Illustrated by Mike Chappell. UK: Osprey Publishing. ISBN 1-84176-196-6. Weeks, John (1979). World War II Small Arms. New York: Galahad Books. ISBN 0-88365-403-2.
=== Mortality === CRE resistance depends upon a number of factors such as the health of the patient, whether the patient has recently undergone a transplant, risk of co-infection, and use of multiple antibiotics. Carbapenem minimal inhibitory concentrations (MICs) results may be more predictive of clinical patient outcomes than the current categorical classification of the MICs being listed as susceptible, intermediate, or resistant. The study aimed to define an all-cause hospital mortality breakpoint for carbapenem MICs that were adjusted for risk factors. Another objective was to determine if a similar breakpoint existed for indirect outcomes, such as the time to death and length of stay after infection for survivors. Seventy-one patients were included, of which 52 patients survived and 19 patients died. Classification and regression tree analysis determined a split of organism MIC between 2 and 4 mg/liter and predicted differences in mortality (16.1% for 2 mg/liter versus 76.9% for 4 mg/liter). In logistic regression controlling for confounders, each imipenem MIC doubling dilution doubled the probability of death. This classification scheme correctly predicted 82.6% of cases. Patients were accordingly stratified to MICs of ≤2 mg/liter (58 patients) and ≥4 mg/liter (13 patients). Patients in the group with a MIC of ≥4 mg/liter tended to be more ill. Secondary outcomes were also similar between groups. Patients with organisms that had an MIC of ≥4 mg/liter had worse outcomes than those with isolates of an MIC of ≤2 mg/liter.
Sources: en.wikipedia.org
The Downstream-peptide motif refers to a conserved RNA structure identified by bioinformatics in the cyanobacterial genera Synechococcus and Prochlorococcus and one phage that infects such bacteria. It was also detected in marine samples of DNA from uncultivated bacteria, which are presumably other species of cyanobacteria. Downstream-peptide RNAs are found upstream of short open reading frames (ORFs) that are predicted to encode short peptides (usually between 17 and 100 amino acids). One of the ORFs is apparently down-regulated when cells are grown with an insufficient supply of nitrogen sources. The Downstream-peptide motif has a structural resemblance to a different candidate RNA structure called the glnA RNA motif which was shown to be a functional glutamine binding riboswitch in cyanobacteria. The most striking similarity is the nucleotide conservation within the P1 stem of both motifs, and this and other similarities was discussed previously. It was hypothesized that Downstream-peptide RNAs correspond to riboswitches, based on multiple lines of evidence. First, glnA RNAs are often located in the presumed 5′ untranslated regions of multiple classes of genes involved in nitrogen metabolism. This, and other evidence, suggests that glnA RNAs are riboswitches, and their structural similarity to Downstream-peptide RNAs in turn suggests that Downstream-peptide RNAs are also riboswitches.
Birds are tetrapods but though their hind limbs are used for walking or hopping, their front limbs are wings covered with feathers and adapted for flight. Birds are endothermic, have a high metabolic rate, a light skeletal system and powerful muscles. The long bones are thin, hollow and very light. Air sac extensions from the lungs occupy the centre of some bones. The sternum is wide and usually has a keel and the caudal vertebrae are fused. There are no teeth and the narrow jaws are adapted into a horn-covered beak. The eyes are relatively large, particularly in nocturnal species such as owls. They face forwards in predators and sideways in ducks. The feathers are outgrowths of the epidermis and are found in localized bands from where they fan out over the skin. Large flight feathers are found on the wings and tail, contour feathers cover the bird's surface and fine down occurs on young birds and under the contour feathers of water birds. The only cutaneous gland is the single uropygial gland near the base of the tail. This produces an oily secretion that waterproofs the feathers when the bird preens. There are scales on the legs, feet and claws on the tips of the toes.
Analogues of MDMA include amphetamine, methamphetamine, homopiperonylamine (MDPEA), homarylamine (MDMPEA), lophophine (MMDPEA), MDA, MMDA, MMDA-2, DMMDA, DMMDA-2, MDEA, MDOH, MDMOH (FLEA), N-t-BOC-MDMA, methylone (MDMC), MBDB, 5-MAPB, 6-MAPB, 5-MAPBT, 6-MAPBT, SDMA, ODMA, SeDMA, TDMA, MDAI, and MDAT, among many others. Deuterated analogues of MDMA such as d2-MDMA have been described as well.
== Cast == Karl Urban as Dredd: A famed and feared Judge. Producer Allon Reich described Dredd as "an extreme character, and he administers justice with an extreme lack of prejudice". Urban approached the producers about joining the film. He found the role challenging because the character never removes his helmet, requiring Urban to convey emotion without using his eyes. He viewed the character as an average man with an insanely tough job in a fragmenting society and likened Dredd's heroism to that of a fireman. The role also demanded physical preparation; Urban undertook intensive physical training to become a "beast of a man". He also underwent weapons and technical training to learn how to operate under fire, arrest criminals and breach doors. He insisted on performing his own motorcycle stunts for the film. He played Dredd with a raspy and harsh vocal tone akin to "a saw cutting through bone", which he found difficult to sustain.
Sources: en.wikipedia.org
Provided the monosaccharide amino acid building block is stable to peptide coupling conditions, amine deprotection conditions and resin cleavage. Linear assembly remains a popular strategy for the synthesis of glycopeptides with many examples in the literature. In the convergent assembly strategy a peptide chain and glycan residue are first synthesis separately. Then the glycan is glycosylated onto a specific residue of the peptide chain. This approach is not as popular as the linear strategy due to the poor reaction yields in the glycosylation step. Another strategy to produce glycopeptide libraries is using Glyco-SPOT synthesis technique. The technique extends the existing method of SPOT synthesis. In this method, libraries of glycopeptides are produced on a cellulose surface (e.g. filter paper) which acts as the solid phase. The glycopeptides are produced by spotting FMOC protected amino acids allowing the synthesis to be performed at microgram (nanomole) scale using very small amounts of glycoamino acids. The scale of this technique can be an advantage for creating libraries for screening by using less amounts of glycoamino acids per peptide. However to produce larger quantities of glycopeptides traditional resin-based solid phase techniques would be better.
From measurements and based on the positions of the footprints, the animal was believed to be traveling at a walking speed of around 2.8 to 5 miles per hour and was estimated to have a hip height of 1.56 to 2.06 m (5.1 to 6.8 ft). A follow-up paper appeared in 2017, increasing the speed estimations by 50–80%. Rare fossil footprints and trackways found in New Mexico and Wyoming that are assigned to the ichnogenus Tyrannosauripus have been attributed to being made by Tyrannosaurus, based on the stratigraphic age of the rocks they are preserved in. The first specimen, found in 1994 was described by Lockley and Hunt and consists of a single, large footprint. Another pair of ichnofossils, described in 2021, show a large tyrannosaurid rising from a prone position by rising up using its elbows in conjunction with the pads on their feet to stand. These two unique sets of fossils were found in Ludlow, Colorado and Cimarron, New Mexico. Another ichnofossil described in 2018, perhaps belonging to a juvenile Tyrannosaurus or Nanotyrannus was uncovered in the Lance Formation of Wyoming. The trackway itself offers a rare glimpse into the walking speed of tyrannosaurids, and the trackmaker is estimated to have been moving at a speed of 4.5–8.0 kilometers per hour (2.8–5.0 mph), significantly faster than previously assumed for estimations of walking speed in tyrannosaurids.
HMB is believed to reduce muscle protein breakdown in humans by inhibiting the 19S and 20S subunits of the ubiquitin–proteasome system in skeletal muscle and by inhibiting apoptosis of skeletal muscle nuclei via unidentified mechanisms. Based upon animal studies, HMB appears to be metabolized within skeletal muscle into cholesterol, which may then be incorporated into the muscle cell membrane, thereby enhancing membrane integrity and function. The effects of HMB on muscle protein metabolism may help stabilize muscle cell structure. One review suggested that the observed HMB-induced reduction in the plasma concentration of muscle damage biomarkers (i.e., muscle enzymes such as creatine kinase and lactate dehydrogenase) in humans following intense exercise may be due to a cholesterol-mediated improvement in muscle cell membrane function. HMB has been shown to stimulate the proliferation, differentiation, and fusion of human myosatellite cells in vitro, which potentially increases the regenerative capacity of skeletal muscle, by increasing the protein expression of certain myogenic regulatory factors (e.g., myoD and myogenin) and gene transcription factors (e.g., MEF2). HMB-induced human myosatellite cell proliferation in vitro is mediated through the phosphorylation of the mitogen-activated protein kinases ERK1 and ERK2. HMB-induced human myosatellite differentiation and accelerated fusion of myosatellite cells into muscle tissue in vitro is mediated through the phosphorylation of Akt, a serine/threonine-specific protein kinase.
Hosokawa Micron Powder Systems is an American company located in Summit, New Jersey, which designs and manufactures equipment for size reduction, classification and mixing of chemical, pharmaceutical and food materials. The company was started in 1923 by Louis Ruprecht named Pulverizing Company and was later bought by the Hosokawa Micron Group in 1985.
The death penalty should be discretionary for the offences where the death sentence is mandatory – murder, drug trafficking, firearms offences and sedition – a position similar to that for the offence of kidnapping. There are strong arguments for changing the mandatory nature of capital punishment in Singapore. Judges should be given the discretion to impose the death penalty only where deemed appropriate.
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
Reversed-phase HPLC separates the sample into peaks, and the main peak is expressed as a percentage of total peak area. Mass spectrometry is then used to confirm that the molecular mass matches the expected value.